Table 1.
Baseline characteristics between AF patients with cancer and without cancer before PSM.
| Variables | Total (n = 9,159) | No Cancer (n = 8,749) | Cancer (n = 410) | P-value | SMD |
|---|---|---|---|---|---|
| Age, years | 65.72 (11.35) | 65.46 (11.38) | 71.18 (9.18) | <0.001 | 0.623 |
| Male, n (%) | 5,328 (58.17) | 5,117 (58.49) | 211 (51.46) | 0.005 | −0.141 |
| Hospital stays, days | 6.28 (3.96) | 6.28 (3.95) | 6.19 (4.06) | 0.64 | −0.023 |
| Smoking, n (%) | 1,790 (19.77) | 1,725 (19.96) | 65 (15.89) | 0.044 | −0.106 |
| Drinking, n (%) | 1,240 (13.7) | 1,191 (13.78) | 49 (11.98) | 0.30 | −0.051 |
| SBP, mmHg | 134.17 (19.06) | 134.14 (19.07) | 134.70 (18.85) | 0.57 | 0.029 |
| DBP, mmHg | 81.47 (16.58) | 81.52 (16.72) | 80.43 (13.23) | 0.19 | −0.082 |
| Hemoglobin count, g/L | 140.79 (16.43) | 141.08 (16.29) | 134.43 (17.98) | <0.001 | −0.370 |
| Platelet count, ×109/L | 200.38 (50.54) | 200.68 (50.24) | 193.89 (56.20) | 0.008 | −0.121 |
| NLR | 1.86 (1.46, 2.40) | 1.86 (1.46, 2.39) | 1.86 (1.59, 2.67) | 0.002 | 0.099 |
| TC, mmol/L | 4.57 (0.77) | 4.58 (0.77) | 4.47 (0.75) | 0.005 | −0.146 |
| TG, mmol/L | 1.43 (0.71) | 1.44 (0.72) | 1.35 (0.53) | 0.015 | −0.164 |
| LDL-C, mmol/L | 2.58 (0.56) | 2.58 (0.56) | 2.49 (0.55) | 0.002 | −0.163 |
| HDL-C, mmol/L | 1.21 (0.24) | 1.21 (0.24) | 1.18 (0.24) | 0.021 | −0.113 |
| ALT, IU/L | 28.63 (48.69) | 28.85 (49.71) | 24.03 (14.42) | 0.050 | −0.334 |
| AST, IU/L | 26.40 (47.03) | 26.50 (48.06) | 24.35 (10.98) | 0.37 | −0.196 |
| eGFR, ml/min/1.73m2 | 87.20 (23.56) | 87.34 (23.47) | 84.08 (25.34) | 0.011 | −0.129 |
| SUA, μmol/L | 364.03 (93.86) | 364.40 (93.96) | 356.11 (91.38) | 0.080 | −0.091 |
| K+, mmol/L | 4.02 (0.39) | 4.02 (0.39) | 4.05 (0.44) | 0.080 | 0.083 |
| Na+, mmol/L | 141.91 (2.66) | 141.92 (2.64) | 141.54 (3.08) | 0.013 | −0.125 |
| Mg2+, mmol/L | 0.93 (0.09) | 0.93 (0.09) | 0.92 (0.09) | 0.20 | −0.082 |
| FBG, mmol/L | 5.77 (1.81) | 5.76 (1.81) | 5.90 (1.79) | 0.26 | 0.075 |
| Coagulation indicators | |||||
| TT, s | 21.37 (19.17) | 21.38 (19.20) | 21.23 (18.63) | 0.89 | −0.008 |
| PT, s | 13.61 (6.30) | 13.61 (6.34) | 13.48 (5.33) | 0.69 | −0.026 |
| APTT, s | 28.20 (9.40) | 28.12 (7.27) | 30.00 (28.44) | 0.21 | 0.066 |
| Fib, g/L | 2.84 (0.69) | 2.83 (0.68) | 2.98 (0.87) | <0.001 | 0.173 |
| TSH, mIU/L | 2.69 (3.33) | 2.67 (2.98) | 3.12 (7.64) | 0.28 | 0.060 |
| BNP, ng/L | 189.83 (264.05) | 188.94 (266.06) | 208.77 (216.19) | 0.14 | 0.092 |
| Echocardiographic parameters | |||||
| LAD, mm | 40.58 (5.97) | 40.58 (5.99) | 40.55 (5.64) | 0.94 | −0.005 |
| LVEDD, mm | 48.14 (5.71) | 48.16 (5.73) | 47.64 (5.29) | 0.14 | −0.098 |
| LVEF,% | 55.18 (7.56) | 55.16 (7.61) | 55.61 (6.46) | 0.33 | 0.069 |
| Previous history, n (%) | |||||
| HTN | 5,181 (56.57) | 4,918 (56.21) | 263 (64.15) | 0.002 | 0.165 |
| CHD | 3,321 (36.26) | 3,186 (36.42) | 135 (32.93) | 0.15 | −0.074 |
| HF | 2,296 (25.07) | 2,179 (24.91) | 117 (28.54) | 0.097 | 0.080 |
| Stroke | 945 (10.32) | 897 (10.25) | 48 (11.71) | 0.34 | 0.045 |
| PAD | 157 (1.71) | 154 (1.76) | 3 (0.73) | 0.12 | −0.121 |
| Dyslipidemia | 5,624 (61.4) | 5,376 (61.45) | 248 (60.49) | 0.70 | −0.020 |
| T2DM | 1,846 (20.16) | 1,739 (19.88) | 107 (26.10) | 0.002 | 0.142 |
| CKD | 851 (9.29) | 793 (9.06) | 58 (14.15) | <0.001 | 0.146 |
| Hyperthyroidism | 182 (1.99) | 173 (1.98) | 9 (2.20) | 0.76 | 0.015 |
| Hypothyroidism | 119 (1.3) | 112 (1.28) | 7 (1.71) | 0.46 | 0.033 |
| VTE | 28 (0.31) | 24 (0.27) | 4 (0.98) | 0.04 | 0.071 |
| COPD | 68 (0.74) | 65 (0.74) | 3 (0.73) | 1.000 | −0.001 |
| Types of AF, n (%) | 0.78 | ||||
| PaAF | 5,277 (57.62) | 5,038 (57.58) | 239 (58.29) | 0.014 | |
| PeAF | 3,882 (42.38) | 3,711 (42.42) | 171 (41.71) | −0.014 | |
| Antiarrhythmic drugs, n (%) | 0.038 | ||||
| Amiodarone | 2,728 (29.78) | 2,629 (30.05) | 99 (24.15) | −0.138 | |
| Propafenone | 1,419 (15.49) | 1,351 (15.44) | 68 (16.59) | 0.031 | |
| β-blocker | 5,012 (54.72) | 4,769 (54.51) | 243 (59.27) | 0.097 | |
| Anticoagulants, n (%) | 0.35 | ||||
| Warfarin | 4,741 (51.76) | 4,538 (51.87) | 203 (49.51) | −0.047 | |
| NOACs | 4,418 (48.24) | 4,211 (48.13) | 207 (50.49) | 0.047 | |
| AF radiofrequency ablation, n (%) | 3,003 (32.79) | 2,910 (33.26) | 93 (22.68) | <0.001 | −0.253 |
Abbreviations: AF, atrial fibrillation; ALT, alanine transaminase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BNP, B-type natriuretic peptide; CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; Fib, plasma fibrinogen; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; HTN, hypertension; LAD, left atrial diameter; LDL-C, low-density lipoprotein cholesterol; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; NLR, neutrophil to lymphocyte ratio; NOACs, non-vitamin K antagonist oral anticoagulants; PaAF, paroxysmal atrial fibrillation; PAD, peripheral arterial disease; PeAF, persistent atrial fibrillation; PSM, Propensity score matching; PT, prothrombin time; SBP, systolic blood pressure; SMD, standardized mean difference; SUA, serum uric acid; T2DM, type2 diabetes mellitus; TC, total cholesterol; TG, triglyceride; TT, thrombin time; TSH, thyroid stimulating hormone; VTE, venous thromboembolism.